The effects of apomorphine on paracetamol-induced hepatotoxicity in rats.

The effects of apomorphine on paracetamol-induced hepatotoxicity in rats. Cell Mol Biol (Noisy-le-grand). 2017 Dec 30;63(12):40-44 Authors: Sehitoglu MH, Yayla M, Kiraz A, Oztopuz RO, Bayir Y, Karaca T, Khalid S, Akpinar E Abstract It is becoming progressively more understandable that overdose of paracetamol in both humans and animals causes severe hepatotoxicity. Apomorphine is known as a neuroprotective agent. Due to the protective effect,  apomorphine had been tested in experimental studies on different models. Findings obtained through series of expriments suggested that apomorphine may also be useful in liver toxicity. The aim of this study is to investigate the relationship among the hepatoprotective mechanism of apomorphine and to determine the possible role of apomorphine on paracetamol-induced hepatotoxicity in rats. 30 Sprague Dawley rats (adult male) were distributed into 5 groups. Group 1 was the control group and did not receive any medication. Group 2 received only paracetamol 2 g/kg by intragastric gavage to induce hepatotoxicity. Groups 3 and 4 were given apomorphine 1 mg/kg and 2 mg/kg by intraperitoneal injection, respectively. Groups 3 and 4 were given 2g/kg  of Paracetamol. In Group 5, rats were treated with 2 mg/kg of apomorphine. Drug-treated rats were given food for the next 24 h until they were sacrified. Moreover, we also performed AST, ALT measurements in serum, MDA and SOD levels in liver tissues and histopathological ...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Related Links:

BACKGROUND: High overdose mortality after release from state prison systems is well documented; however, little is known about overdose mortality following release from local criminal justice systems (CJS). The purpose of this study was to assess overdose ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
No abstract available
Source: The Back Letter - Category: Orthopaedics Tags: Articles Source Type: research
We report a 29-year-old man with clinical stage 1 HIV infection who had been started on DTG, tenofovir and emtricitabine eight months prior, and who was admitted following a suicidal overdose of 1500 mg o f DTG. He reported only minor symptoms including vomiting, epigastric pain and dizziness; which promptly resolved following supportive treatment. On admission, full blood count, liver function tests and electrocardiography were unremarkable. However, there was a non-progressive increase in serum cre atinine. After a month off ARVs, he was successfully restarted on antiretroviral therapy without any serious adverse effect.
Source: Southern African Journal of HIV Medicine - Category: African Health Authors: Source Type: research
Abstract AH-7921 is a synthetic opioid that was developed in the early 1970s. It has resulted in several fatal and nonfatal intoxications, despite not having approval from the US Food and Drug Administration. To date, AH-7921 is listed as a schedule I drug, and there have been no clinical trials exploring the safety of AH-7921. Herein, we provide an analysis of existing case reports available in the literature regarding AH-7921. We searched PubMed, Scopus, Web of Science, and EBSCO for articles (up until December 2017) using the terms "AH-7921" and "AH7921." In total, 48 articles were identifie...
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Tags: Proc (Bayl Univ Med Cent) Source Type: research
The Overdose Prevention and Patient Safety Act would break down the firewall that prevents doctors from learning of a patient's substance use disorder.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Planning grants designed to strengthen the capacity of multi-sector consortia to address prevention, treatment, and recovery from substance use disorder, including opioid use disorder in rural counties identified to be at the highest risk. The overall goal of the program is to reduce the morbidity and mortality associated with opioid overdoses in high-risk rural communities. Geographic coverage: Nationwide -- Federal Office of Rural Health Policy, Health Resources and Services Administration, U.S. Department of Health and Human Services
Source: Funding opportunities via the Rural Health Information Hub - Category: American Health Source Type: funding
Attorney general of state with third-highest drug overdose rate blasts chain's dual role as distributor and pharmacy
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
The program aims to address the opioid crisis by increasing access to medication-assisted treatment using the three FDA-approved medications for the treatment of opioid use disorder, reducing unmet treatment need, and reducing opioid overdose related deaths through the provision of prevention, treatment and recovery activities for opioid use disorder (OUD).
Source: HSR Information Central - Category: International Medicine & Public Health Source Type: news
Correction of technical and typographical errors in a final rule published on April 16, 2018. The original rule revised the Medicare Advantage (MA) program (Part C) regulations and Prescription Drug Benefit program (Part D) to implement provisions designed to reduce beneficiary misuse or overdose of opioids as part of the Comprehensive Addiction and Recovery Act (CARA). It included information on changes to improve program integrity policies related to payments in MA, Medicare cost plan, Part D, and PACE programs, among other things. It also included CMS's response to comments submitted on the final rule, including its eff...
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
The Health Resources and Services Administration (HRSA) Federal Office of Rural Health Policy (FORHP) released the Notice of Funding Opportunity (NOFO) for the new Rural Communities Opioid Response (Planning) (RCORP) initiative for FY 2018. HRSA plans to award approximately 75 grants through this funding opportunity, with successful awardees receiving up to $200,000 for one year to develop plans to implement opioid use disorder prevention, treatment, and recovery interventions designed to reduce opioid overdoses among rural populations.
Source: News stories via the Rural Assistance Center - Category: Rural Health Source Type: news
More News: Biology | Brain | Liver | Molecular Biology | Neurology | Overdose | Study | Toxicology | Urology & Nephrology